Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi

Contraception. 2019 Nov;100(5):402-405. doi: 10.1016/j.contraception.2019.07.144. Epub 2019 Jul 30.

Abstract

Objective: To compare medroxyprogesterone acetate (MPA) concentrations between HIV-positive women on antiretroviral therapy (ART) and HIV-negative women initiating depot medroxyprogesterone (DMPA) injectable.

Study design: Secondary analysis of 28 HIV-positive women on non-nucleoside reverse transcriptase inhibitor-containing ART regimens and 10 HIV-negative women randomized to initiate DMPA in a clinical trial of progestin contraception in Malawi.

Results: MPA concentrations were significantly lower among HIV-positive women on ART, compared with HIV-negative women, at week 4 and week 13 (p=.03 for both), but not at day 3 or week 26 post-DMPA initiation.

Conclusions: Antiretroviral medications may affect MPA metabolism in HIV-positive African women.

Trial registration: ClinicalTrials.gov NCT02103660.

Keywords: Africa; Antiretroviral therapy; Depot medroxyprogesterone acetate; HIV.

Publication types

  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use*
  • Contraception / methods
  • Contraceptive Agents, Female / pharmacokinetics*
  • Contraceptive Agents, Female / therapeutic use
  • Delayed-Action Preparations
  • Female
  • HIV Infections / drug therapy*
  • Humans
  • Malawi
  • Medroxyprogesterone Acetate / pharmacokinetics*
  • Medroxyprogesterone Acetate / therapeutic use
  • Progestins / therapeutic use*
  • Treatment Outcome
  • Young Adult

Substances

  • Anti-HIV Agents
  • Contraceptive Agents, Female
  • Delayed-Action Preparations
  • Progestins
  • Medroxyprogesterone Acetate

Associated data

  • ClinicalTrials.gov/NCT02103660